Nuron Biotech acquires Meningitec vaccine from Pfizer

Nuron Biotech has expanded its vaccine portfolio with the acquisition of Meningitec from Pfizer

Specialty vaccines company Nuron Biotech has acquired meningitis vaccine Meningitec from Pfizer.

Meningitec is designed to prevent invasive disease caused by Neisseria meningitidis serogroup C, a major cause of invasive bacterial disease in Europe and the Americas.

The preservative-free vaccine is delivered via intramuscular injection from ready-to-use pre-filled syringes and more than 50 million doses have been distributed since its launch.

It is registered in 23 countries and helped to reduce disease caused by N. meningitidis serogroup C by 93 per cent in children in the UK in the early 2000s, according to Richard Dinovitz, vice-president of marketing and business development at Nuron Biotech.

He revealed: "We are planning to expand into markets with unvaccinated and under-vaccinated populations, helping us address public health needs around the world."

Dr Shankar Musunuri, Nuron Biotech's chief executive officer and founder, added that the acquisition of Meningitec represents a "tremendous opportunity" to expand the company's portfolio.